Drug Profile
MB 191
Alternative Names: Angiogenesis inhibitor gene medicineLatest Information Update: 15 Jan 2002
Price :
$50
*
At a glance
- Originator Valentis
- Developer University of California at San Francisco; Valentis
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Jan 2002 Suspended - Preclinical for Cancer in USA (Intratumoural)
- 22 Jun 1999 The Megabios/GeneMedicine merged company is now called Valentis
- 29 Mar 1999 Megabios has merged with GeneMedicine